MA45149A - Méthodes de traitement de la maladie d'alzheimer - Google Patents

Méthodes de traitement de la maladie d'alzheimer

Info

Publication number
MA45149A
MA45149A MA045149A MA45149A MA45149A MA 45149 A MA45149 A MA 45149A MA 045149 A MA045149 A MA 045149A MA 45149 A MA45149 A MA 45149A MA 45149 A MA45149 A MA 45149A
Authority
MA
Morocco
Prior art keywords
alzheimer
disease
treatment
methods
Prior art date
Application number
MA045149A
Other languages
English (en)
French (fr)
Inventor
Brendon Phillip Boot
Jeffrey Joseph Sevigny
Leslie Lugene Williams
Original Assignee
Biogen Int Neuroscience Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Int Neuroscience Gmbh filed Critical Biogen Int Neuroscience Gmbh
Publication of MA45149A publication Critical patent/MA45149A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
MA045149A 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer MA45149A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662346818P 2016-06-07 2016-06-07
US201662435531P 2016-12-16 2016-12-16

Publications (1)

Publication Number Publication Date
MA45149A true MA45149A (fr) 2019-04-10

Family

ID=59067640

Family Applications (1)

Application Number Title Priority Date Filing Date
MA045149A MA45149A (fr) 2016-06-07 2017-06-06 Méthodes de traitement de la maladie d'alzheimer

Country Status (12)

Country Link
US (2) US20200308259A1 (enExample)
EP (1) EP3464350A1 (enExample)
JP (3) JP2019517540A (enExample)
KR (2) KR20230165883A (enExample)
CN (3) CN114796481A (enExample)
AU (2) AU2017276656A1 (enExample)
BR (1) BR112018075300A2 (enExample)
CA (1) CA3026598A1 (enExample)
IL (1) IL263433B2 (enExample)
MA (1) MA45149A (enExample)
MX (1) MX2018015022A (enExample)
WO (1) WO2017211827A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201827467A (zh) 2016-11-03 2018-08-01 比利時商健生藥品公司 焦穀胺酸類澱粉蛋白－β之抗體及其用途
EP3696192A1 (en) 2019-02-15 2020-08-19 Consejo Superior De Investigaciones Científicas Therapeutic target and monoclonal antibodies against it for the diagnosis and treatment of alzheimer´s disease
KR20210143858A (ko) 2019-03-26 2021-11-29 얀센 파마슈티카 엔.브이. 피로글루타메이트 아밀로이드-β에 대한 항체 및 이의 용도
CN110511276A (zh) * 2019-08-13 2019-11-29 王跃驹 植物作为宿主在表达Aducanumab抗体中的应用
JOP20220092A1 (ar) * 2019-10-22 2023-01-30 Biogen Ma Inc جسم مضاد لبيتا-النشواني لعلاج مرض الزهايمر
CN116348487A (zh) 2020-07-23 2023-06-27 欧萨尔普罗席纳有限公司 抗淀粉样β抗体
KR102321601B1 (ko) * 2020-11-19 2021-11-05 주식회사 휴런 뇌 영상을 이용한 알츠하이머병의 생물학적 분류 장치 및 방법
WO2022261026A2 (en) * 2021-06-07 2022-12-15 Biogen Ma Inc. Methods for treating alzheimer's disease
US20250122146A1 (en) * 2021-09-30 2025-04-17 The Scripps Research Institute Compounds for reducing neuroinflammation
MX2024005999A (es) * 2021-11-19 2024-05-30 Ap Biosciences Inc Anticuerpos bispecificos dirigidos a cd137 y usos de los mismos para la inmunoterapia anticancer.

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20160049045A (ko) * 2006-07-14 2016-05-04 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
PL2426143T3 (pl) 2007-01-05 2017-12-29 University Of Zurich Sposób zapewniania specyficznych wobec choroby cząsteczek wiążących i celów
ES2686550T3 (es) 2010-10-11 2018-10-18 Biogen International Neuroscience Gmbh Anticuerpos anti-tau humanos
KR102308915B1 (ko) * 2012-10-15 2021-10-06 메디뮨 리미티드 아밀로이드 베타에 대한 항체
KR20150127570A (ko) * 2012-12-07 2015-11-17 바이오겐 인터내셔널 뉴로사이언스 게엠베하 항-Aβ 항체를 이용하여 뇌 아밀로이드 플락을 감소시키는 방법
US9598484B2 (en) 2012-12-21 2017-03-21 Biogen Ma Inc. Human anti-tau antibodies
KR20230056800A (ko) * 2014-02-08 2023-04-27 제넨테크, 인크. 알츠하이머 질환을 치료하는 방법
MA41115A (fr) * 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer

Also Published As

Publication number Publication date
JP2025160337A (ja) 2025-10-22
US20200308259A1 (en) 2020-10-01
CN114796481A (zh) 2022-07-29
CN114931635A (zh) 2022-08-23
WO2017211827A1 (en) 2017-12-14
AU2024216442A1 (en) 2024-10-17
BR112018075300A2 (pt) 2019-04-30
JP2019517540A (ja) 2019-06-24
AU2017276656A1 (en) 2018-12-13
IL263433A (en) 2019-01-31
IL263433B1 (en) 2023-11-01
IL263433B2 (en) 2024-03-01
CA3026598A1 (en) 2017-12-14
EP3464350A1 (en) 2019-04-10
US20220281963A1 (en) 2022-09-08
KR20190021311A (ko) 2019-03-05
JP2022145965A (ja) 2022-10-04
CN109476730A (zh) 2019-03-15
KR20230165883A (ko) 2023-12-05
MX2018015022A (es) 2019-08-14

Similar Documents

Publication Publication Date Title
EP3645121A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
MA45149A (fr) Méthodes de traitement de la maladie d'alzheimer
EP3515505A4 (en) AAV TREATMENT BY MORBUS ALZHEIMER
MA41115A (fr) Procédé de traitement de la maladie d'alzheimer
EP3458589A4 (en) COMPOSITIONS AND METHODS FOR TREATING MORBUS HUNTINGTON
EP3291815A4 (en) METHOD FOR TREATING A NEURODEEGENERATIVE DISEASE
EP3490582A4 (en) METHOD AND COMPOSITIONS FOR TREATING MYELOFIBROSE
EP3813808A4 (en) Methods of treating substance abuse
EP3644996A4 (en) METHOD OF TREATMENT FOR HUNTINGTON'S MORBUS
EP3534907A4 (en) COMPOSITIONS AND METHODS FOR TREATING LIVER DISEASES
EP3528852A4 (en) METHOD AND COMPOSITIONS FOR TREATING MORBUS FABRY
EP3294345A4 (en) TPP1 FORMULATIONS AND METHOD FOR THE TREATMENT OF CLN2 DISEASES
EP3019523A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND MORBUS HUNTINGTON
EP3452166A4 (en) INTRANASAL STIMULATION FOR THE TREATMENT OF DISEASES OF MEIBOM'S GLANDS AND BLEPHARITIS
EP3377118A4 (en) METHOD FOR THE TREATMENT OF MORBUS ALZHEIMER AND RELATED DISEASES
EP3402533A4 (en) METHOD AND COMPOSITIONS FOR TREATING NEUROLOGICAL DISEASE
EP3846830A4 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF MUSCULOSKELETAL DISEASES
MA53329A (fr) Méthodes de traitement de l'épilepsie
EP2978446A4 (en) METHOD AND MEANS FOR THE TREATMENT OF MORBUS ALZHEIMER
LT3463351T (lt) Parkinsono ligos gydymas
PL3347002T3 (pl) Leczenie choroby alzheimera w konkretnej populacji pacjentów
EP3386520A4 (en) METHOD FOR THE TREATMENT OF EYE DISEASES OR DISORDERS
EP3393468A4 (en) METHOD FOR TREATING AN IMMUNE WEAKNESS
EP3454793A4 (en) TREATMENT COILS FOR ANEURYSMS
MA46353A (fr) Méthodes de traitement de l'infertilité féminine